Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Boehringer Ingelheim
AstraZeneca
Express Scripts
Mallinckrodt

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Farletuzumab

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Farletuzumab: Sponsors, patents, clinical trial progress

Farletuzumab is an investigational drug.

There have been 8 clinical trials for Farletuzumab. The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2009.

The most common disease conditions in clinical trials are Ovarian Neoplasms, Hypersensitivity, and Neoplasms, Glandular and Epithelial. The leading clinical trial sponsors are Morphotek, Eisai Co., Ltd., and [disabled in preview].

Recent Clinical Trials for Farletuzumab
TitleSponsorPhase
A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian CancerEisai Co., Ltd.Phase 2
A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian CancerMorphotekPhase 2
A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the LungMorphotekPhase 2

See all Farletuzumab clinical trials

Clinical Trial Summary for Farletuzumab

Top disease conditions for Farletuzumab
Top clinical trial sponsors for Farletuzumab

See all Farletuzumab clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Express Scripts
Moodys
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.